• Please log in or register to access this feature.

Research Article

Prognostic utility of autoantibodies to α-enolase and Hsp70 for cancer of the gingivo-buccal complex using immunoproteomics

  1. Atul Pranay1,
  2. Sanjeev Shukla1,†,
  3. Sadhana Kannan1,
  4. Siddhi A. Malgundkar1,
  5. Rukmini B. Govekar1,
  6. Asawari Patil1,2,
  7. Shubhada V. Kane2,
  8. Pankaj Chaturvedi2,
  9. Anil K. D'Cruz2,
  10. Surekha M. Zingde1,*

Article first published online: 1 MAR 2013

DOI: 10.1002/prca.201200081

Additional Information

How to Cite

Pranay, A., Shukla, S., Kannan, S., Malgundkar, S. A., Govekar, R. B., Patil, A., Kane, S. V., Chaturvedi, P., D'Cruz, A. K. and Zingde, S. M. (2013), Prognostic utility of autoantibodies to α-enolase and Hsp70 for cancer of the gingivo-buccal complex using immunoproteomics. Prot. Clin. Appl.. doi: 10.1002/prca.201200081

Author Information

  1. 1

    Advanced Centre for Treatment,, Research and Education in Cancer (ACTREC),, Tata Memorial Centre, Kharghar, Navi Mumbai, India

  2. 2

    Tata Memorial Hospital,, Tata Memorial Centre, Parel, Mumbai, India

  1. †

    Current address: Centre for Cancer Research, Mouse Cancer Genetics Program, National Cancer Institute Frederick, MD, USA.

*Correspondence: Dr. Surekha M. Zingde, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India
E-mail: szingde@actrec.gov.in
Fax: +91-22-27405095

  1. †

    Current address: Centre for Cancer Research, Mouse Cancer Genetics Program, National Cancer Institute Frederick, MD, USA.

Publication History

  1. Article first published online: 1 MAR 2013
  2. Accepted manuscript online: 17 NOV 2012 05:54AM EST
  3. Manuscript Accepted: 26 OCT 2012
  4. Manuscript Revised: 11 OCT 2012
  5. Manuscript Received: 9 AUG 2012

Funded by

  • Council of Scientific and Industrial Research. Grant Number: 27(0151)/06/EMR-II
  • ACTREC
  • Lady Tata Memorial Trust
  • ACTREC
  • ACTREC

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (779K)

Keywords:

  • Alpha-enolase;
  • Autoantibodies;
  • Hsp70;
  • Oral cancer;
  • Prognosis

Purpose

Studies from our laboratory have reported 14 tumor antigens that elicit an autoantibody response in patients with cancer of the gingivobuccal complex (GBC) In this study, utility of the autoantibody response has been evaluated for prognosis of cancer of the GBC.

Experimental design

Autoantibody response was evaluated using immunoproteomics and the prognostic significance was assessed by Kaplan-Meier survival and multivariate analysis.

Results

Autoantibody response against α-enolase isoforms a, b, and c and Hsp70 was detected in 27, 53, 64, and 26% of the 78 patients, respectively. Patients positive for autoantibody response to α-ENO and Hsp70 individually and in combination, showed significantly reduced disease-free survival (DFS) compared to those who do not show autoantibody response to either of them. Further the patients, who exhibit autoantibody response to α-ENO and Hsp70 in combination with nodal involvement and/or differentiation status, have significantly lowered DFS. The relative risk of recurrence is 3.41 for patients who exhibit autoantibody response to both the antigens.

Conclusions and clinical relevance

Autoantibody response against α-ENO and Hsp70 provides an additional parameter and may be utilized along with nodal involvement and differentiation status for better prognosis of cancer of GBC.

View Full Article with Supporting Information (HTML) Get PDF (779K)